分子病理学
克拉斯
ROS1型
医学
SMARCA4型
肺癌
病理
分子诊断学
疾病
肺
阶段(地层学)
病态的
癌症
外科病理学
腺癌
内科学
生物信息学
结直肠癌
生物
基因
染色质
生物化学
染色质重塑
古生物学
作者
Elizabeth Paver,Sandra A. O’Toole,Xin Cheng,Annabelle Mahar,Wendy A. Cooper
标识
DOI:10.1053/j.semdp.2021.04.001
摘要
An understanding of the molecular pathology of non-small cell lung cancer (NSCLC) is important for pathologists as molecular characterization is now required for treatment decisions in advanced stage disease. While assessment for EGFR mutations, ALK and ROS1 fusions, and in some countries BRAF mutations, is now standard practice, other oncogenic mutations are also emerging that may impact routine clinical practice including alterations involving KRAS, NTRK, RET, MET and HER2. In addition, molecular pathology alterations of NSCLC are associated with responses to immune checkpoint therapy and are being increasingly investigated. Finally, specific molecular pathological alterations define some rarer subtypes of NSCLC such as salivary gland tumours, NUT carcinoma and SMARCA4-deficient undifferentiated tumour, and an understanding of the molecular pathology is important for their accurate diagnosis. In this review, the molecular pathology of NSCLC is discussed with a focus on clinically relevant molecular alterations.
科研通智能强力驱动
Strongly Powered by AbleSci AI